Search

Your search keyword '"Ray-Coquard, Isabelle"' showing total 2,286 results
Start Over Author "Ray-Coquard, Isabelle"
2,286 results on '"Ray-Coquard, Isabelle"'

351. Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG

Author

Karabajakian, Andy, Genestie, Catherine, Meeus, Pierre, Guyon, Frédéric, Llacer Moscardo, Carmen, Croce, Sabrina, Taieb, Sophie, Duffaud, Florence, Pautier, Patricia, Ray-Coquard, Isabelle, and Blay, Jean-Yves

Abstract

L’adénosarcome utérin est une tumeur maligne rare biphasique composée à la fois d’un composant cellulaire stromal sarcomateux et de cellules épithéliales bénignes. Le stade de la maladie est déterminé par l’invasion du myomètre et le degré d’extension extra-utérine et utilise la classification FIGO. Les facteurs histopronostiques les plus importants sont l’existence d’un « sarcomatous overgrowth » (SO) défini par un contingent sarcomateux occupant plus de 25 % du volume de la tumeur (directement corrélé au grade de la maladie), la présence d’une composante hétérologue et/ou de haut grade. Les adénosarcomes de stade I sans sur-représentation sarcomateuse ont un bon pronostic, avec une survie globale à cinq ans proche de 80 %. La résection chirurgicale complète est préconisée pour les stades localisés. La place de l’hormonothérapie, la chimiothérapie et la radiothérapie adjuvante n’est pas établie. Les rechutes doivent, dans la mesure du possible, être à nouveau traitées chirurgicalement, avec l’objectif d’une résection complète. Dans les stades avancés inopérables ou métastatiques, l’hormonothérapie est une option importante pour les adénosarcomes de bas grade avec surexpression des récepteurs d’œstrogènes et/ou de progestérone. Pour les tumeurs de haut grade, les chimiothérapies de référence sont les associations à base de doxorubicine, bien qu’une approche intégrée de la chirurgie et des traitements systémiques doivent également être envisagée dans ce contexte.

Published
2023
Full Text
View/download PDF

352. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer: Alexandra Leary.

Author

Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, and Yeste-Velasco, Marc

Subjects
ENDOMETRIAL cancer, MTOR inhibitors, CARBOPLATIN, AUTOPHAGY, PACLITAXEL
Abstract

This document is a correction notice for an article titled "ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer" published in BMC Cancer. The authors reported that the equal contribution statement was missing in the original submission, and they have provided the correct equal contribution statement. The correction does not make any claims about jurisdictional or institutional affiliations. The article was authored by Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán, Paloma Martin-Martorell, Ernest Nadal, Pere Gascón, Jordi Rodon, Jose M Lizcano, Pau Muñoz-Guardiola, Gemma Fierro-Durán, Oriol Pedrós-Gámez, Héctor Pérez-Montoyo, Marc Yeste-Velasco, Marc Cortal, Antonio Pérez-Campos, Jose Alfon, Carles Domenech, Alejandro Pérez-Fidalgo, and Ana Oaknin. [Extracted from the article]

Published
2024
Full Text
View/download PDF

353. DOMENICA study (GINECO-EN105b/ENGO-Ten13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1).

Author

Chel Hun Choi, Ray-Coquard, Isabelle, Rubio, Maria Jesus, Paoletti, Xavier, Hudson, Emma, Lorusso, Domenica, Hasler-Strub, Ursula, Vardar, Mehmet Ali, Lheureux, Stéphanie, Van Gorp, Toon, Shao Peng Tan, David, Trillsch, Fabian, Eberst, Lauriane, Lescure, Céline, Hardy-Bessard, Anne-Claire, Chaix, Marie, Byoung-Gie Kim, JaeWeon Kim, JeongYeol Park, and Jung-Yun Lee

Subjects
*CLINICAL trials, *ENDOMETRIAL cancer, *ENDOMETRIAL surgery, *IMMUNOTHERAPY, *ANAPLASTIC thyroid cancer, *PROGRESSION-free survival, *OVERALL survival, *COMBINATION drug therapy
Abstract

Objective: The standard treatment for advanced endometrial cancer (EC) includes platinum-based combination chemotherapy (CT), regardless of the histology, molecular status and the patient's profile. However, EC patients are a particularly frail group of patients, often with co-morbidities. Tolerance of CT can be difficult and induce long-term toxicities. In advanced EC disease, anti-PD1 immunotherapy has shown impressive results amongst mismatch repair deficient (MMRd)/high microsatellite instability (MSI-H) tumors. However, the benefit of adding CT to anti-PD1 is still an opened question. The aim of DOMENICA is to address the question if PD-1 alone has superior efficacy to CT, so that therapy in 1L advanced/recurrent MMRd/MSI-H EC could be de-escalated to avoid CT related toxicities. Methods: DOMENICA is an academic international randomized open-label, phase III trial evaluating the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient (MMRd/MSI-H) relapse or advanced / metastatic EC. Inclusion criteria for the study comprised patients with histologically confirmed EC exhibiting recurrent or advanced disease, including primary stage IIIA to C2 or Stage IV disease, or experiencing their first recurrence of EC without curative treatment, provided they had evaluable disease according to RECIST 1.1 criteria. Additionally, patients with MMRd/MSI-H tumors, determined by institutional MMR immunohistochemistry testing, and those with a performance status (ECOG) of 0-1 were eligible. The primary endpoint is progression-free survival according to RECIST 1.1, assessed by the BICR (Blinded Independent Central Review). Secondary endpoints include overall survival as key secondary endpoint, progression-free survival 2, patients reported outcome, best objective response rate, disease control rate, duration of response rate, safety and tolerability, time to first or second subsequent treatment (TFST, TSST), pharmacokinetics and immunogenicity of dostarlimab. Exploratory objectives include predictive biomarkers, efficacy according to geriatric status. The Study is ongoing in France (GINECO), Spain (GEICO), Italy (MaNGO, MITO), Canada (PMC), Singapore (GCIG), South Korea (KGOG), Japan (GOTIC), Turkey (TRSGO), and UK (NRCI). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

354. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Author

Schöffski, Patrick, Ray-Coquard, Isabelle Laure, Cioffi, Angela, Bui, Nguyen Bin, Bauer, Sebastian, Hartmann, Joerg Thomas, Krarup-Hansen, Anders, Grünwald, Viktor, Sciot, Raf, Dumez, Herlinde, Blay, Jean-Yves, Le Cesne, Axel, Wanders, Jantien, Hayward, Carolyn, Marreaud, Sandrine, Ouali, Monia, and Hohenberger, Peter

Published
2011
Full Text
View/download PDF

358. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

Author

Romeo, Clémence, primary, Le Saux, Olivia, additional, Jacobs, Margaux, additional, Joly, Florence, additional, Ferron, Gwenael, additional, Favier, Laure, additional, Fumet, Jean-David, additional, Isambert, Nicolas, additional, Colombo, Pierre-Emmanuel, additional, Sabatier, Renaud, additional, Bastide, Ludovic, additional, Charreton, Amandine, additional, Devouassoux-Shisheboran, Mojgan, additional, Gertych, Witold, additional, Dubot, Coraline, additional, Bello Roufai, Diana, additional, Bataillon, Guillaume, additional, Berton, Dominique, additional, Kalbacher, Elsa, additional, Pautier, Patricia, additional, Pomel, Christophe, additional, Cornou, Caroline, additional, Treilleux, Isabelle, additional, Lardy-Cleaud, Audrey, additional, and Ray-Coquard, Isabelle, additional

Published
2022
Full Text
View/download PDF

360. Survival Prognostic and Surrogate Values of the Early Modeled Ca-125 Kelim Score in First-Line Treatment of Ovarian Cancer: Results from The Gcig Individual Patient Data Meta-Analysis

Author

Corbaux, Pauline, primary, You, Benoit, additional, Glasspool, Rosalind M., additional, Yanaihara, Nozomu, additional, Tinker, Anna V., additional, Lindemann, Kristina, additional, Ray-Coquard, Isabelle-Laure, additional, Mirza, Mansoor Raza, additional, Subtil, Fabien, additional, Colomban, Olivier, additional, Péron, Julien, additional, Karamouza, Eleni, additional, McNeish, Iain, additional, Hinsley, Samantha, additional, Kagimura, Tatsuo, additional, Welch, Stephen, additional, Lewsley, Liz-Anne, additional, Paoletti, Xavier, additional, and Cook, Adrian, additional

Published
2022
Full Text
View/download PDF

361. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

Author

Trédan, Olivier, primary, Provansal, Magali, additional, Abdeddaim, Cyril, additional, Lardy-Cleaud, Audrey, additional, Hardy-Bessard, Anne-Claire, additional, Kalbacher, Elsa, additional, Floquet, Anne, additional, Venat-Bouvet, Laurence, additional, Lortholary, Alain, additional, Pop, Oana, additional, Frenel, Jean-Sébastien, additional, Cancel, Mathilde, additional, Largillier, Rémy, additional, Louvet, Christophe, additional, You, Benoît, additional, Zannetti, Alain, additional, Anota, Amelie, additional, Treilleux, Isabelle, additional, Pissaloux, Daniel, additional, Houlier, Aurélie, additional, Savoye, Aude-Marie, additional, Mouret-Reynier, Marie-Ange, additional, Meunier, Jérôme, additional, Levaché, Charles-Briac, additional, Brocard, Fabien, additional, and Ray-Coquard, Isabelle, additional

Published
2022
Full Text
View/download PDF

362. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Author

Cassier, Philippe A., primary, Peyramaure, Clémentine, additional, Attignon, Valery, additional, Eberst, Lauriane, additional, Pacaud, Camille, additional, Boyault, Sandrine, additional, Desseigne, Françoise, additional, Sarabi, Mathieu, additional, Guibert, Pierre, additional, Rochefort, Pauline, additional, Marques, Nathalie, additional, Rivoire, Michel, additional, Dupré, Aurélien, additional, Peyrat, Patrice, additional, Terret, Catherine, additional, Ray-Coquard, Isabelle, additional, Coutzac, Clélia, additional, Pérol, David, additional, Blay, Jean-Yves, additional, Trédan, Olivier, additional, and de la Fouchardière, Christelle, additional

Published
2022
Full Text
View/download PDF

363. Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Author

Toulmonde, Maud, primary, Brahmi, Mehdi, additional, Giraud, Antoine, additional, Chakiba, Camille, additional, Bessede, Alban, additional, Kind, Michèle, additional, Toulza, Emilie, additional, Pulido, Marina, additional, Albert, Sabrina, additional, Guégan, Jean-Philippe, additional, Cousin, Sophie, additional, Mathoulin-Pelissier, Simone, additional, Perret, Raul, additional, Croce, Sabrina, additional, Blay, Jean-Yves, additional, Ray-Coquard, Isabelle, additional, Floquet, Anne, additional, and Italiano, Antoine, additional

Published
2021
Full Text
View/download PDF

364. Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)

Author

Sebbag, Clara, primary, Rousset-Jablonski, Christine, additional, Coussy, Florence, additional, Ray-Coquard, Isabelle, additional, Garin, Clementine, additional, Evrevin, Clemence, additional, Toussaint, Aullene, additional, Cessot, Marion, additional, Labrosse, Julie, additional, Laot, Lucie, additional, Darrigues, Lauren, additional, Bobrie, Angelique, additional, Jacob, William, additional, Senechal, Claire, additional, Espie, Marc, additional, Giacchetti, Sylvie, additional, Charveriat, Patrick, additional, Plu-Bureau, Genevieve, additional, Maitrot, Lorraine, additional, Gompel, Anne, additional, Chapron, Charles, additional, Santulli, Pietro, additional, Asselain, Bernard, additional, Hotton, Judicael, additional, Coutant, Charles, additional, Guerin, Julien, additional, Decanter, Christine, additional, Mailliez, Audrey, additional, Delrieu, Lidia, additional, Dumas, Elise, additional, Sablone, Laura, additional, Reyal, Fabien, additional, and Hamy-Petit, Anne-sophie, additional

Published
2021
Full Text
View/download PDF

366. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Author

Swisher, Elizabeth M., primary, Kristeleit, Rebecca S., additional, Oza, Amit M., additional, Tinker, Anna V., additional, Ray-Coquard, Isabelle, additional, Oaknin, Ana, additional, Coleman, Robert L., additional, Burris, Howard A., additional, Aghajanian, Carol, additional, O'Malley, David M., additional, Leary, Alexandra, additional, Welch, Stephen, additional, Provencher, Diane, additional, Shapiro, Geoffrey I., additional, Chen, Lee-may, additional, Shapira-Frommer, Ronnie, additional, Kaufmann, Scott H., additional, Goble, Sandra, additional, Maloney, Lara, additional, Kwan, Tanya, additional, Lin, Kevin K., additional, and McNeish, Iain A., additional

Published
2021
Full Text
View/download PDF

369. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

Author

Kwan, Tanya T., primary, Oza, Amit M., additional, Tinker, Anna V., additional, Ray-Coquard, Isabelle, additional, Oaknin, Ana, additional, Aghajanian, Carol, additional, Lorusso, Domenica, additional, Colombo, Nicoletta, additional, Dean, Andrew, additional, Weberpals, Johanne, additional, Severson, Eric, additional, Vo, Lan-Thanh, additional, Goble, Sandra, additional, Maloney, Lara, additional, Harding, Thomas, additional, Kaufmann, Scott H., additional, Ledermann, Jonathan A., additional, Coleman, Robert L., additional, McNeish, Iain A., additional, Lin, Kevin K., additional, and Swisher, Elizabeth M., additional

Published
2021
Full Text
View/download PDF

371. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Author

Gaillard, Stephanie, primary, Oaknin, Ana, additional, Ray-Coquard, Isabelle, additional, Vergote, Ignace, additional, Scambia, Giovanni, additional, Colombo, Nicoletta, additional, Fernandez, Cristian, additional, Alfaro, Vicente, additional, Kahatt, Carmen, additional, Nieto, Antonio, additional, Zeaiter, Ali, additional, Aracil, Miguel, additional, Vidal, Laura, additional, Pardo-Burdalo, Beatriz, additional, Papai, Zsuzsanna, additional, Kristeleit, Rebecca, additional, O'Malley, David M., additional, Benjamin, Ivor, additional, Pautier, Patricia, additional, and Lorusso, Domenica, additional

Published
2021
Full Text
View/download PDF

372. Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study

Author

Pujade-Lauraine, Eric, primary, Fujiwara, Keiichi, additional, Ledermann, Jonathan A., additional, Oza, Amit M., additional, Kristeleit, Rebecca, additional, Ray-Coquard, Isabelle-Laure, additional, Richardson, Gary E., additional, Sessa, Cristiana, additional, Yonemori, Kan, additional, Banerjee, Susana, additional, Leary, Alexandra, additional, Tinker, Anna V., additional, Jung, Kyung Hae, additional, Madry, Radoslaw, additional, Park, Sang-Yoon, additional, Anderson, Charles K., additional, Zohren, Fabian, additional, Stewart, Ross A., additional, Wei, Caimiao, additional, Dychter, Samuel S., additional, and Monk, Bradley J., additional

Published
2021
Full Text
View/download PDF

373. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer

Author

Vergote, Ignace, primary, Ray-Coquard, Isabelle, additional, Anderson, Daniel M., additional, Cantuaria, Guilherme, additional, Colombo, Nicoletta, additional, Garnier-Tixidre, Claire, additional, Gilbert, Lucy, additional, Harter, Philipp, additional, Hettle, Robert, additional, Lorusso, Domenica, additional, Mäenpää, Johanna, additional, Marth, Christian, additional, Matsumoto, Koji, additional, Ouwens, Mario, additional, Poveda, Andrés, additional, Raspagliesi, Francesco, additional, Rhodes, Kirsty, additional, Rubio Pérez, María J., additional, Shapira-Frommer, Ronnie, additional, Shikama, Ayumi, additional, Sikorska, Magdalena, additional, Moore, Kathleen, additional, and DiSilvestro, Paul, additional

Published
2021
Full Text
View/download PDF

374. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

Author

O'Malley, David M., primary, Oaknin, Ana, additional, Monk, Bradley J., additional, Selle, Frédéric, additional, Rojas, Carlos, additional, Gladieff, Laurence, additional, Berton, Dominique, additional, Leary, Alexandra, additional, Moore, Kathleen N., additional, Estevez-Diz, Maria D.P., additional, Hardy-Bessard, Anne-Claire, additional, Alexandre, Jérôme, additional, Opperman, Christina P., additional, de Azevedo, Carla Rameri A.S., additional, Randall, Leslie M., additional, Feliu, Waldo Ortuzar, additional, Ancukiewicz, Marek, additional, and Ray-Coquard, Isabelle, additional

Published
2021
Full Text
View/download PDF

375. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Author

Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony, Mezni, Essia, Evans, Catherine Karine, Chinot, Olivier, Loschi, Alain, Arnaud, Sylvie, Mellinas, Marie, Bay, Jacques-Olivier, Bouleuc, Carole, Firmin, Nelly, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Penel, Nicolas, Rodrigues, Manuel, Thiery-Vuillemin, Antoine, Wislez, Marie, L’allemain, Gilles, Robert, Jacques, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen, Monk, Bradley, Oaknin, Ana, Tinker, Anna, Gilbert, Lucy, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, de Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, de La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, Rousset-Rouviere, Sandrine, Rochigneux, Philippe, Chrétien, Anne-Sophie, Fattori, Stéphane, Gorvel, Laurent, Provansal, Magali, Lambaudie, Eric, Olive, Daniel, Martin, Johan, Guérin, Mathilde, Monneur, Audrey, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Bidard, François-Clément, Mari, Roxane, Narducci, Fabrice, Cappiello, Maria-Antonietta, Rousseau, Fréderique, Blache, Guillaume, Birnbaum, Daniel, Cropet, C., Montegut, C., Frindte, J., Cinieri, S., Guerra-Alia, E.M., Bogner, G., Yoshida, H., Vergote, I., Hietanen, S., Largillier, R., Canzler, U., Gratet, A., Marmé, F., Pujade-Lauraine, E., Favier, L., Ray-Coquard, I.L., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, First line, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, medicine.disease, Olaparib, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, business, Ovarian cancer, medicine.drug
Abstract

International audience; 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884.

Published
2021

377. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

Author

Penel, Nicolas, Ray-Coquard, Isabelle, Bal-Mahieu, Christine, Chevreau, Christine, Le Cesne, Axel, Italiano, Antoine, Bompas, Emmanuelle, Clisant, Stéphanie, Baldeyrou, Brigitte, Lansiaux, Amélie, Robin, Yves-Marie, Bay, Jacques-Olivier, Piperno-Neumann, Sophie, Blay, Jean-Yves, and Fournier, Charles

Published
2014
Full Text
View/download PDF

378. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region

Author

Heudel, Pierre Etienne, Cousin, Philippe, Lurkin, Antoine, Cropet, Claire, Ducimetiere, Françoise, Collard, Olivier, De Laroche, Guy, Biron, Pierre, Meeus, Pierre, Thiesse, Philippe, Bergeron, Christophe, Vaz, Gualter, Mithieux, François, Farsi, Fadila, Fayet, Yohan, Gilly, François-Noel, Cellier, Dominic, Blay, Jean-Yves, and Ray-Coquard, Isabelle

Published
2014
Full Text
View/download PDF

380. Heritable defects in telomere and mitotic function selectively predispose to sarcomas.

Author

Ballinger, Mandy L., Pattnaik, Swetansu, Mundra, Piyushkumar A., Zaheed, Milita, Rath, Emma, Priestley, Peter, Baber, Jonathan, Ray-Coquard, Isabelle, Isambert, Nicholas, Causeret, Sylvain, van der Graaf, Winette T. A., Puri, Ajay, Duffaud, Florence, Le Cesne, Axel, Seddon, Beatrice, Chandrasekar, Coonoor, Schiffman, Joshua D., Brohl, Andrew S., James, Paul A., and Kurtz, Jean-Emmanuel

Published
2023
Full Text
View/download PDF

381. Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.

Author

Mourksi, Nour‐El‐Houda, Dalban, Cécile, Colombe‐Vermorel, Amélie, Odeyer, Laetitia, Simioni, Valentin, Frenel, Jean‐Sébastien, Fabbro, Michel, Bazan, Fernando, Abadie‐Lacourtoisie, Sophie, Coquan, Elodie, Martinez, Séverine, Garin, Gwenaelle, Tabone‐Eglinger, Séverine, Treilleux, Isabelle, Chabaud, Sylvie, Pérol, David, Ray‐Coquard, Isabelle, Heudel, Pierre‐Etienne, Diaz, Jean‐Jacques, and Marcel, Virginie

Abstract

Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression‐free rate compared to Anastrozole alone. However, a better patient selection based on biomarkers would improve patient outcome. We evaluate for the first time the usage of ribosome biogenesis (RiBi) factors as a source of innovative markers. Using 47 FFPE tumours (A n = 18; V + A n = 29), 32 blood samples (A n = 13; V + A n = 19) and 30 samples of total RNAs (A n = 12; V + A n = 18) from the VICTORIA clinical trial, we observed an association between RiBi‐associated markers and drug activity or prediction of treatment response. NOP10 and NHP2 mRNA levels were significantly higher in non‐responders compared to responders in the Vistusertib + Anastrozole arm (P = 0.0194 and P = 0.0002 respectively; i.e. 8 weeks progression‐free survival as endpoint). This study provides RiBi‐based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

382. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.

Author

Chvetzoff, Gisèle, Bouleuc, Carole, Lardy-Cléaud, Audrey, Saltel, Pierre, Dieras, Véronique, Morelle, Magali, Guastalla, Jean-Paul, Tredan, Olivier, Rebattu, Paul, Pop, Simona, Ray-Coquard, Isabelle, Pierga, Jean-Yves, Mignot, Laurent, Laurence, Valérie, Bourne-Branchu, Valérie, Pérol, David, and Bachelot, Thomas

Abstract

Purpose: The most appropriate criteria and timing for palliative care referral remain a critical issue, especially in patients with metastatic breast cancer for whom long-term chemosensibility and survival are observed. We aimed to compare the impact of early palliative care including formal concertation with oncologists on decision for an additional line of chemotherapy compared with usual oncology care. Methods: This randomized prospective study enrolled adult women with metastatic breast cancer and visceral metastases with a 3rd- or 4th-line chemotherapy (CT). Patients received usual oncology care with a palliative care consultation only upon patient or oncologist request (standard group, S) or were referred to systematic palliative care consultation including a regular concertation between palliative care team and oncologists (early palliative care group, EPC). The primary endpoint was the rate of an additional CT (4th or 5th line) decision. Quality of life, symptoms, social support and satisfaction were self-evaluated at 6 and 12 months, at treatment discontinuation or 3 months after discontinuation. Results: From January 2009 to November 2012, two authorized cancer centers included 98 women (EPC: 50; S: 48). Thirty-seven (77.1%, 95%CI 62.7–88%) patients in the EPC group had a subsequent chemotherapy prescribed and 36 (72.0%, 95%CI 57.5–83.8%) in the S group (p = 0.646). No differences in symptom control and global quality of life were observed, but less deterioration in physical functioning was reported in EPC (EPC: 0 [− 53–40]; S: − 6; 7 [− 60 to − 20]; p = 0.027). Information exchange and communication were significant improved in EPC (exchange, EPC: − 8.3 [− 30 to + 7]; S: 0.0 [− 17 to + 23]; p = 0.024; communication, EPC: 12.5 [− 8 to − 37]; S: 0.0 [− 21 to + 17]; p = 0.004). Conclusion: EPC in metastatic breast cancer patients did not impact the prescription rate of additional chemotherapy in patients a 3rd- or 4th-line chemotherapy for metastatic breast cancer; however, EPC may contribute to alleviate deterioration in physical functioning, while facilitating communication. Trial registration: ClinicalTrial.gov identifier: NCT00905281, May 20, 2009. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

387. Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Author

Pasquali, Sandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin‐Broto, Javier, additional, Lopez‐Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Tendero, Oscar, additional, Diaz‐Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Infante, Gabriele, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Bianchi, Giuseppe, additional, Marrari, Andrea, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, Miceli, Rosalba, additional, Casali, Paolo Giovanni, additional, Gronchi, Alessandro, additional, Dani, Carla, additional, Villa, Chiara, additional, Messina, Antonella, additional, Rusi, Lorella, additional, Nuzzo, Anna Maria, additional, Nuzzo, Carmen, additional, De Paoli, Antonino, additional, Buonadonna, Angela, additional, Comandone, Alessandro, additional, Boglione, Antonella, additional, Livi, Lorenzo, additional, Greto, Daniela, additional, Riva, Nada, additional, Monti, Manuela, additional, Pennacchioli, Elisabetta, additional, De Pas, Tommaso, additional, Ippolito, Vincenzo, additional, Ledesma, Patrico, additional, Redondo, Andres, additional, Valverde, Claudia, additional, Bratos, Raquel, additional, Cruz, Josefina, additional, Martinez Trufero, Javier, additional, Cubedo, Ricardo, additional, Sevilla, Isabel, additional, Luna, Pablo, additional, Lopez, Rafael, additional, Sancho, Pilar, additional, Bally, Olivia, additional, Brahmi, Mehdi, additional, Ray‐Coquard, Isabelle, additional, Cassier, Philippe, additional, Marques, Nathalie, additional, Tassy, Luis, additional, Boudou‐Rouquette, Pascaline, additional, Tlemsani, Camille, additional, Alexandre, Jerome, additional, Goldwasser, Francois, additional, Bompas, Emmanuelle, additional, Rolland, Frederic, additional, Perrin, Christophe, additional, Talarmin, Marie, additional, Italiano, Antoine, additional, Toulmonde, Maud, additional, Laramas, Mathieu, additional, Bay, Jacques‐Olivier, additional, Dubray‐Longeras, Pascale, additional, and Rutkowski, Piotr, additional

Published
2021
Full Text
View/download PDF

388. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database

Author

De Nonneville, Alexandre, primary, Zemmour, Christophe, additional, Frank, Sophie, additional, Joly, Florence, additional, Ray-Coquard, Isabelle, additional, Costaz, Hèlène, additional, Classe, Jean-Marc, additional, Floquet, Anne, additional, De la Motte Rouge, Thibault, additional, Colombo, Pierre-Emmanuel, additional, Sauterey, Baptiste, additional, Leblanc, Eric, additional, Pomel, Christophe, additional, Marchal, Frédéric, additional, Barranger, Emmanuel, additional, Savoye, Aude-Marie, additional, Guillemet, Cécile, additional, Petit, Thierry, additional, Pautier, Patricia, additional, Rouzier, Roman, additional, Gladieff, Laurence, additional, Simon, Gaëtane, additional, Courtinard, Coralie, additional, and Sabatier, Renaud, additional

Published
2021
Full Text
View/download PDF

389. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer

Author

Winkler, Claudia, primary, King, Matthew, additional, Berthe, Julie, additional, Ferraioli, Domenico, additional, Garuti, Anna, additional, Grillo, Federica, additional, Rodriguez-Canales, Jaime, additional, Ferrando, Lorenzo, additional, Chopin, Nicolas, additional, Ray-Coquard, Isabelle, additional, Delpuech, Oona, additional, Bedognetti, Davide, additional, Ballestrero, Alberto, additional, Leo, Elisabetta, additional, and Zoppoli, Gabriele, additional

Published
2021
Full Text
View/download PDF

391. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer

Author

Lecuelle, Julie, primary, Boidot, Romain, additional, Mananet, Hugo, additional, Derangère, Valentin, additional, Albuisson, Juliette, additional, Goussot, Vincent, additional, Arnould, Laurent, additional, Tharin, Zoé, additional, Ray Coquard, Isabelle, additional, Ghiringhelli, François, additional, Truntzer, Caroline, additional, and Fumet, Jean-David, additional

Published
2021
Full Text
View/download PDF

392. RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma

Author

Hietanen, Sakari, primary, Pautier, Patricia, additional, Harter, Philipp, additional, Cropet, Claire, additional, Cinieri, Saverio, additional, Caballero, Cristina, additional, Marth, Christian, additional, Fujiwara, Hiroyuki, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Lotz, Jean-Pierre, additional, Gropp-Meier, Martina, additional, Mosconi, Anna Maria, additional, Manso, Luis, additional, Lefeuvre-Plesse, Claudia, additional, Lück, Hans-Joachim, additional, Lortholary, Alain, additional, Schnelzer, Andreas, additional, Dubot, Coraline, additional, and Ray-Coquard, Isabelle, additional

Published
2021
Full Text
View/download PDF

393. Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

Author

Pujade-Lauraine, Eric, primary, Brown, Jessica, additional, Barnicle, Alan, additional, Rowe, Phil, additional, Lao-Sirieix, Pierre, additional, Criscione, Steven, additional, du Bois, Andreas, additional, Lorusso, Domenica, additional, Romero, Ignacio, additional, Petru, Edgar, additional, Yoshida, Hiroyuki, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Hietanen, Sakari, additional, Provansal, Magali, additional, Schmalfeldt, Barbara, additional, Pignata, Sandro, additional, Martin-Lorente, Cristina, additional, Berton, Dominique, additional, Runnebaum, Ingo, additional, and Ray-Coquard, Isabelle, additional

Published
2021
Full Text
View/download PDF

394. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

Author

Makker, Vicky, primary, Colombo, Nicoletta, additional, Herráez, Antonio Casado, additional, Santin, Alessandro, additional, Colomba, Emeline, additional, Miller, David, additional, Fujiwara, Keiichi, additional, Pignata, Sandro, additional, Baron-Hay, Sally, additional, Ray-Coquard, Isabelle, additional, Shapira-Frommer, Ronnie, additional, Ushijima, Kimio, additional, Sakata, Jun, additional, Yonemori, Kan, additional, Kim, Yong Man, additional, Guerra, Eva, additional, Sanli, Ulus, additional, McCormack, Mary, additional, Huang, Jie, additional, Smith, Alan, additional, Keefe, Stephen, additional, Dutta, Lea, additional, Orlowski, Robert, additional, and Lorusso, Domenica, additional

Published
2021
Full Text
View/download PDF

395. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Lièvre, Astrid, primary, Turpin, Anthony, additional, Ray-Coquard, Isabelle, additional, Le Malicot, Karine, additional, Thariat, Juliette, additional, Ahle, Guido, additional, Neuzillet, Cindy, additional, Paoletti, Xavier, additional, Bouché, Olivier, additional, Aldabbagh, Kais, additional, Michel, Pierre, additional, Debieuvre, Didier, additional, Canellas, Anthony, additional, Wislez, Marie, additional, Laurent, Lucie, additional, Mabro, May, additional, Colle, Raphael, additional, Hardy-Bessard, Anne-Claire, additional, Mansi, Laura, additional, Colomba, Emeline, additional, Bourhis, Jean, additional, Gorphe, Philippe, additional, Pointreau, Yoann, additional, Idbaih, Ahmed, additional, Ursu, Renata, additional, Di Stefano, Anna Luisa, additional, Zalcman, Gérard, additional, Aparicio, Thomas, additional, Moulin, Solenne, additional, Leleu, Olivier, additional, Leparree, Sylvie, additional, Goasdoue, Henri, additional, Piprot, Christine, additional, Tourneur, Gerald, additional, Bayart, Vincent, additional, Lignier, Delphine, additional, Lachaier, Emma, additional, Khamari, Marwa, additional, Coutte, Alexandre, additional, Siembida, Nicolas, additional, Houessinon, Aline, additional, Regimbeau, Jean Marc, additional, Chauffert, Bruno, additional, Moreira, Aurélie, additional, Hautefeuille, Vincent, additional, Hee, Christine, additional, Boone, Mathieu, additional, Bihan, Céline, additional, Chive, Emilie, additional, Poulet-Potriquier, Stéphane, additional, Fahem, Rachida, additional, Luet, Dominique, additional, Roquin, Guillaume, additional, Vitellius, Carole, additional, Cornet-Trichereau, Nathanaëlle, additional, Caroli-Bosc, François-Xavier, additional, Thirot-Bidault, Anne, additional, Ropert, Stanislas, additional, Gachet - Masson, Julie, additional, Dehais, Mélanie, additional, L'helgoualc'h, Gwen-Ael, additional, Ali-Mahamadou, Ibrahim, additional, Talfi, Safia, additional, Belmont, Laure, additional, Kilendo, Dieudonné, additional, Benrezzak, Nasro, additional, Dubief, Emeline, additional, Conroy, Guillaume, additional, Delique, Laurence, additional, Basso, Maud, additional, Pons, Isabelle, additional, Salignon, Karine, additional, Villing, Anne-Laure, additional, Mougenot, Emmanuelle, additional, Porebski, Cassandra, additional, Guiatni, Asma, additional, Cloarec, Nicolas, additional, Mineur, Laurent, additional, Bouchaud, Marie, additional, David, Céleste, additional, Peytier, Annie, additional, Greletty, Thomas, additional, Audemar, Franck, additional, Vignes, Emanuelle, additional, Minne, Floriane, additional, Goldzak, Guillaume, additional, Huysman, Fabienne, additional, Hocine, Fayçal, additional, Lakkis, Zaher, additional, Meynard, Guillaume, additional, Almotlak, Hamadi, additional, Klajer, Elodie, additional, Sun, Xu-Shan, additional, Wasselin, Julie, additional, Catala, Pascale, additional, Mazuy, Claire, additional, Vandamme, Hélène, additional, Prevost, Jean-Briac, additional, Fadin, Aurélie, additional, Basson, Laurent, additional, Huguet, Jean-Baptiste, additional, Dos Santos, Emmanuelle, additional, Jany, Bérangère, additional, Saad, Alain, additional, Goutorbe, Frédéric, additional, Oziol, Eric, additional, Ramdani, Mohamed, additional, Kadiri, Ouafae, additional, Garbay, Delphine, additional, Huet, Clotilde, additional, Giroux Leprieur, Etienne, additional, Teng, Wen, additional, Monvoisin, Justine, additional, Arnaud Coffin, Patrick, additional, Roux, Sylvie, additional, Orfeuvre, Hubert, additional, Chagros, Mélanie, additional, Pillon, Didier, additional, Rassoul, Agathe, additional, Poureau, Pierre Guillaume, additional, Novello, Cécile, additional, Ducray, François, additional, Trouba, Cécile, additional, Bastit, Vianney, additional, Babin, Emmanuel, additional, Leon, Vincent, additional, Courtecuisse, Anne-Catherine, additional, Vambre, Julie, additional, Tack, Vincent, additional, Desauw, Christophe, additional, Meniai, Fatima, additional, Peres, Christina, additional, Esparcieux, Aurélie, additional, Perrier, Hervé, additional, Doux, Nathalie, additional, Kaphan, Régis, additional, Roques, Bertrand, additional, Rebischung, Christine, additional, Mille, Dominique, additional, Fernandes, Gaëlle, additional, Abdelli, Naceur, additional, Jousset, Natacha, additional, Combe, Pierre, additional, Jonveaux, Eric, additional, Dumont, Patrick, additional, Kanaan, Marc, additional, Berthelot Gras, Corinne, additional, Panis, Valérie, additional, Kaluzinski, Laure, additional, Venant-Valery, Marjolène, additional, Lam, You-Heng, additional, Vallee, Laura, additional, Riviere, Frédéric, additional, Durand, Muriel, additional, Benghadid, Dihya, additional, Villeneuve, Emilie, additional, Hentic Dhome, Olivia, additional, Bounouar, Zedjiga, additional, De Mestier, Louis, additional, Dubois, Jacqueline, additional, Eyriey, Magali, additional, Moreau, Lionel, additional, Baihas, Dib, additional, Aldabbagh, Kaïs, additional, Degriffolet, Dominique, additional, Sebbagh, Virginie, additional, Seghezzi, Jean-Christophe, additional, Lozach-Brugirard, Marion, additional, Mandrou, Julie, additional, Mavier, Loubna, additional, Hennetier, Florence, additional, Wagner, Jean-Philippe, additional, Carola, Elisabeth, additional, Chandirakumaran, Karthiga, additional, Loutski, Sandrine, additional, Cojean-Zelek, Isabelle, additional, Bouras, Amina, additional, Lacour, Sandrine, additional, Froura, Fahem, additional, Ben Nadji, Hadjer, additional, Cattelain, Sophie, additional, Darloy, Franck, additional, Jolimoy Boilleau, Geneviève, additional, Maissiat, Cyrielle, additional, Darut-Jouve, Ariane, additional, Lorgis, Véronique, additional, Charifi-Alaoui, Ikram, additional, Ghiringhelli, François, additional, Drouillard, Antoine, additional, Chaix, Marie, additional, Manfredi, Sylvain, additional, Lepage, Côme, additional, Gagnaire, Alice, additional, Latournerie, Marianne, additional, jourdan, Sofia, additional, Perrot, Nora, additional, folia, Mireille, additional, Minello, Anne, additional, Jouve, Jean-Louis, additional, Fery, Marielle, additional, Landau, Alain, additional, Evrard, Diane, additional, Valenza, Bruno, additional, Paitel, Jean-François, additional, Chablais, Laetitia, additional, Kreitmann, Thomas, additional, Lancry-Lecomte, Laurence, additional, Monard, Adrien, additional, Faugeras, Eve, additional, Boucheret, Paul, additional, Glommeau, Cécile, additional, Tchikladze, Christine, additional, Garnier Tixidre, Claire, additional, Long, Jérôme, additional, Zaidi, Manel, additional, Delabarre, Véronique, additional, Meyzenc, Juliette, additional, Ferrand, Loïc, additional, Moro-Sibilot, Denis, additional, Bouheret, Paul, additional, Leyronnas, Cécile, additional, Herve, Camille, additional, Thoor, Audrey, additional, Jacquet, Emanuelle, additional, Roth, Gaël, additional, Madapathage-Senanyake, Videsheka, additional, Chupeau, Peggy, additional, Bieber, Elsa, additional, Rosso, Maud, additional, Lepage, Isabelle, additional, Priou, Frank, additional, Laly, Margot, additional, Aprelon, Sylvie, additional, Sobolak, Natacha, additional, Homokos, Helen, additional, Watelle, Fabienne, additional, Pham-Becker, Alice, additional, Lauridant, Géraldine, additional, Dujardin, Charlotte, additional, Lenglin, Etienne, additional, Nienguet Tsota, Aimée, additional, Dominguez, Sophie, additional, Forestier, Alexandra, additional, Nouvel, Franck, additional, Lerooy, Justine, additional, Ratajczak, Céline, additional, Romano, Olivier, additional, Brzyski, Dorothéee, additional, Barriere, Aurélien, additional, Genet, Dominique, additional, Tisse, Julien, additional, Zasadny, Xavier, additional, Grelet, Adeline, additional, Hennion-Imbault, Amélie, additional, Haustraete, Eglantine, additional, Louafi, Samy, additional, Awad, Manal, additional, Zekri, Younes, additional, Cheneau, Caroline, additional, Leissen, Nolwen, additional, Egreteau, Joëlle, additional, Breant, Alexandra, additional, Sarabi, Matthieu, additional, Labonne, Stéphanie, additional, Forestier, Julien, additional, Leclercq, Céline, additional, Prunier-Bossion, Florence, additional, Ray Coquard, Isabelle, additional, Guillet, Marielle, additional, Theillaumas, Aurélie, additional, Prome, Emilie, additional, Walter, Thomas, additional, Philouze, Pierre, additional, Lawo, Melody, additional, De Talhouet, Solène, additional, Beuvelot, Johanne, additional, Molin, Yann, additional, Bellecoste Martin, Marie, additional, Saussereau, Maud, additional, Agnelli, Lauren, additional, Fakhry, Nicolas, additional, Laplace, Christophe, additional, Norguet Monnereau, Emmanuelle, additional, Boucard, Céline, additional, Djenad, Kahina, additional, Fontaine, Catherine, additional, Seitz, Jean-François, additional, Dahan, Laétitia, additional, Sigrand, Julie, additional, Duluc, Muriel, additional, Locher, Christophe, additional, Fleury, Marjory, additional, Brou Marie, Ange, additional, Berkane, Ramdane, additional, Poupblanc, Séverine, additional, Auby, Dominique, additional, Petran, Daniela, additional, Texereau, Patrick, additional, Guerineau, Elodie, additional, Andre, Morgan, additional, Mahjoubi, Linda, additional, Sarrazin, Fanny, additional, Jeanson, Sonia, additional, Gschwend, Anthony, additional, Birr, Virginie, additional, Fore, Mathieu, additional, Noirclerc, Monique, additional, Dahou, Sihem, additional, Spaeth, Dominique, additional, Lambotin, Mélanie, additional, Lelu, Thomas, additional, Linot, Benjamin, additional, Hugon, Nathalie, additional, Rousseau, Dominique, additional, Castanie, Hélène, additional, Lenne, Carole, additional, Lortholary, Alain, additional, Cessot, Anatole, additional, Merzoug, Messaouda, additional, Naudin, Cécile, additional, Vannetzel, Jean-Michel, additional, Aziz, Ghina, additional, Hadj Arab, Yacine, additional, Pernes, Stéphanie, additional, Roche-Lachaise, Isabelle, additional, Fiteni, Frédéric, additional, Yahiaoui, Hadjer, additional, Marel Lopez, Gwendoline, additional, Oddoz, Jeanne, additional, Peira, Fabienne, additional, Michel, Olivier, additional, Meunier, Jérôme, additional, Ouahrani, Brahim, additional, Roger, Antoine, additional, Branco, Sonia, additional, Nguyen, Van, additional, Gisselbrecht, Mathilde, additional, Hammad, Ghania, additional, Mordant, Pierre, additional, Stroksztejn, Magda, additional, Pocard, Marc, additional, Nlo Meyengue, Luc, additional, Sacco, Emmanuelle, additional, Simon Anne, Sophie, additional, Fabre-Guillevin, Elizabeth, additional, Slim, Marine, additional, Zaanan, Aziz, additional, Cadranel, Jacques, additional, Pluvy, Johan, additional, Ursu, Rénata, additional, Geraldo, Amyrath, additional, Lihi, Rime, additional, Vo, Maryline, additional, Brouk, Zohra, additional, Colle, Raphaël, additional, Bennamoun, Mostefa, additional, Lacan, Fabrice, additional, Louvet, Christophe, additional, Mebarki, Soraya, additional, Veyri, Marianne, additional, Paillaud, Elena, additional, Lucas, Christelle, additional, Dubreuil, Olivier, additional, Lyamani, Jamila, additional, Agguini, Hanane, additional, Soularue, Emilie, additional, Jourdaine, Clément, additional, Verillaud, Benjamin, additional, Herzine, Hakima, additional, Raymond, Eric, additional, Mathiot, Nathalie, additional, Palmieri, Lola Jade, additional, Epanya, Christian, additional, Taieb, Julien, additional, Bertrand, Eliane, additional, Goujon, Gaël, additional, Namour, Céline, additional, Gazeau, Benoit, additional, Zafirova, Biljana, additional, Mirghani, Haitham, additional, Belin, Catherine, additional, Belkhir, Kahina, additional, Gharib, Myriam, additional, Vozy, Aurore, additional, Amrane, Karim, additional, Spano, Jean-Philippe, additional, Wassermann, Johanna, additional, Feuvret, Loic, additional, Bachet, Jean-Baptiste, additional, Philonenko, Sara, additional, Guillot, Laetitia, additional, Zabbe, Marion, additional, Gibiat, Stéphanie, additional, Baylot, Camille, additional, Jouinot, Aude, additional, Leduc, Nicolas, additional, Vieillot, Sabine, additional, James, Laurie, additional, Ducerf, Camille, additional, Blanc, Jean-Frédéric, additional, Falandry Leger, Claire, additional, Wautot, Virginie, additional, Chauvenet, Marion, additional, Vincent, Aude, additional, Tougeron, David, additional, Goulvent, Sandrine, additional, Suc, Etienne, additional, Laurenty, Anne-Pascale, additional, Marquis, Eric, additional, Bonnaire, Margaux, additional, Dewolf, Maxime, additional, Brenet, Esteban, additional, Billard, Delphine, additional, Litre, Claude-Fabien, additional, Dumazet, Antoine, additional, Botsen, Damien, additional, Vazel, Marion, additional, Carlier, Claire, additional, Bonnerave, David, additional, Marchand-Crety, Charles, additional, Bouche, Olivier, additional, Fosse, Patricia, additional, Sefrioui, David, additional, Watson, Sarah, additional, Torche, Fatah, additional, Muron, Thierry, additional, Natur, Stéphane, additional, Desgrippes, Romain, additional, Bihel, Véronique, additional, Ferrand, François-Régis, additional, Leiterer, Caroline, additional, Lavole, Julie, additional, Moquet, Claire, additional, Pressoir, Nathalie, additional, Dziukala, Catherine, additional, Ligeza Poisson, Catherine, additional, Naji, Abdelhalim, additional, Williet, Nicolas, additional, Phelip, Jean-Marc, additional, Di Palma, Fabrice, additional, Kherrour Mehdi, Amina, additional, Langrand-Escure, Julien, additional, Fournel, Pierre, additional, Pigne, Grégoire, additional, Saban-Roche, Léa, additional, Magne, Nicolas, additional, Vassal, Cécile, additional, Jacquin, Jean-Philippe, additional, Ramirez, Carole, additional, Vallard, Alexis, additional, Collard, Olivier, additional, Rivoirard, Romain, additional, Graber, Ivan, additional, Trager Maury, Stéphanie, additional, Duboisset, Elodie, additional, Ayllon Ugarte, Jorge, additional, Rami, Dalilia, additional, Saler, Christine, additional, Reinbolt, Manon, additional, Le Fevre, Clara, additional, Ben Abdelghani, Meher, additional, Dourthe, Louis-Marie, additional, Perruisseau-Carrier, Joffrey, additional, Nguimpi-Tambou, Marlène, additional, Barret, Flavie, additional, Di Stefano Anna, Luisa, additional, Balthazard, Annie, additional, Vassord-Dang, Camille, additional, Le Marchand, Mathilde, additional, Vergniol, Julien, additional, Pripon, Iulia, additional, Daemaegdt, Axelle, additional, Latry, Vanessa, additional, Larrieu, Muna, additional, Landry, Gaëlle, additional, Touihri Maximin, Laetitia, additional, Del Piano, Francesco, additional, Barlet, Agnès, additional, Vernisse, Mylène, additional, Lafond, Sophie, additional, Genin, Charline, additional, Sibertin-Blanc, Camille, additional, Chabrillac, Emilien, additional, Gregoire, Caroline, additional, Vergez, Sébastien, additional, Panouille, Quentin, additional, Guimbaud, Rosine, additional, Richa, Floriane, additional, Lebellec, Loïc, additional, Gounin, Sophie, additional, Buiret, Guillaume, additional, Baudin, Marine, additional, Hamon, Hervé, additional, Deshorgue, Anne-Claire, additional, Barrascout, Eduardo, additional, Legrand, Stéphanie, additional, Houlze, Morgane, additional, Cambula, Linda, additional, Lopez, Anthony, additional, Fouquet, Guillaume, additional, Touabi, Kahina, additional, GermaIn, Adeline, additional, Godbert, Benoit, additional, Voivret, Florence, additional, Perrin, Julie, additional, Da Silva, Rosa, additional, and Bernichon, Emilie, additional

Published
2020
Full Text
View/download PDF

400. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

Author

Bohlius, Julia, Schmidlin, Kurt, Brillant, Corinne, Schwarzer, Guido, Trelle, Sven, Seidenfeld, Jerome, Zwahlen, Marcel, Clarke, Michael, Weingart, Olaf, Kluge, Sabine, Piper, Margaret, Rades, Dirk, Steensma, David P, Djulbegovic, Benjamin, Fey, Martin F, Ray-Coquard, Isabelle, Machtay, Mitchell, Moebus, Volker, Thomas, Gillian, Untch, Michael, Schumacher, Martin, Egger, Matthias, and Engert, Andreas

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results